SCHEMBL6499149

SCHEMBL6499149

COC(=O)N1CCC(OS(C)(=O)=O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 2/20 0.39
▸ CHRNA4 P43681 2/20 0.39
▸ CHRNB4 P30926 1/20 0.39
▸ CHRNA3 P32297 1/20 0.39
▸ PDE4B Q07343 3/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ TSHR P16473 2/20 0.35
▸ EPHX1 P07099 1/20 0.35
▸ PER2 O15055 2/20 0.33
▸ CRY1 Q16526 2/20 0.33
▸ CRY2 Q49AN0 2/20 0.33
▸ BRD4 O60885 2/20 0.33
▸ PKM P14618 1/20 0.33
▸ BRDT Q58F21 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33
▸ MMP1 P03956 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484394 0.90 PDE4B (0.39) CHRNB2CHRNA4CHRNB4CHRNA3PDE4B
SCHEMBL6485850 0.90 PKM (0.41) CHRNB2CHRNA4CHRNB4CHRNA3TP53
SCHEMBL23585416 0.84 GAA (0.47) TP53TSHR
SCHEMBL22686919 0.83 PDE4B (0.35) CHRNB2CHRNA4CHRNB4CHRNA3PDE4B
SCHEMBL1998545 0.83 TP53 (0.32) TP53GPR119
SCHEMBL24174014 0.83 PDE4B (0.35) CHRNB2CHRNA4CHRNB4CHRNA3PDE4B
SCHEMBL2679564 0.83 TP53 (0.32) TP53GPR119
SCHEMBL344785 0.83 TP53 (0.32) TP53GPR119
SCHEMBL29285185 0.83 PDE4B (0.35) CHRNB2CHRNA4CHRNB4CHRNA3PDE4B
SCHEMBL66145 0.83 GPR119 (0.48) EPHX1PIK3CDGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4251620-B1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2025-04-16 — — EP disclosed
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 — — US disclosed
US-6969712-B2 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-29 — — US disclosed
US-20040044056-A1 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-03-04 — — US disclosed
EP-1342717-A1 BENZIMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-09-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044056-A1 Benzimidazole derivatives GPR119, OPRL1, INSR CHRNB2 504/4885CHRNA4 336/4885CHRNB4 444/4885
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 CHRNB2 575/4885CHRNA4 237/4885CHRNB4 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback